Please provide your email address to receive an email when new articles are posted on . In this video, Eunice Wang, MD, discusses the use of venetoclax azacitidine as a standard of care therapy for ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — In this video, Catherine Lai, MD, MPH, spoke with Healio about patients with newly diagnosed or ...

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial Authors retain all ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced new safety and efficacy ...

Evaluation of the Clinical Utility of the Bone Metastases Ensemble Trees for Survival Decision Support Platform (BMETS-DSP): A Case-Based Pilot Assessment Data on 221 newly diagnosed patients with AML ...

Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS. The VERONA (NCT04401748) trial evaluating venetoclax with azacitidine in high-risk ...

Ziftomenib + Venetoclax/Azacitidine in Newly Diagnosed NPM1 -m AML The ongoing KOMET 007 Phase 1a/b trial (NCT05735184) evaluated 40 patients with newly diagnosed NPM1 -m AML as of the September 24, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...